Advertisement

Cardiologie pp 43-49 | Cite as

5 Diabetes mellitus en het metabool syndroom

  • L. Van Gaal
Part of the Quintessens book series (QUI)

Samenvatting

Epidemiologisch wordt het aantal diabetespatiënten in de Verenigde Staten geschat op 35 miljoen, waarbij de prevalentie de komende vijftien tot twintig jaar met meer dan 200% zou toenemen. In België/Nederland wordt de prevalentie op 4% geschat. Dit betekent een niet onbelangrijke toename, zowel in geïndustrialiseerde als in minder geïndustrialiseerde landen: wereldwijd zou het aantal diabetespatiënten in 2025 ongeveer 380 miljoen bedragen.

Literatuur

  1. Aaron I, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476–85.CrossRefGoogle Scholar
  2. American Diabetes Association. The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–97.Google Scholar
  3. American Diabetes Association. The Expert Committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.Google Scholar
  4. Ford E, et al. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care. 2005;28:2745–9.PubMedCrossRefGoogle Scholar
  5. Gaal L van, et al. Mechanisms linking with cardiovascular disease. Nature. 2006;444:875–80.PubMedCrossRefGoogle Scholar
  6. Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.PubMedCrossRefGoogle Scholar
  7. Kahn R, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–304.PubMedCrossRefGoogle Scholar
  8. Mertens I, et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res. 2001;33:602–7.PubMedCrossRefGoogle Scholar
  9. Mogi M, et al. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension. 2006;48:141–8.PubMedCrossRefGoogle Scholar
  10. Ryden L, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88–136.PubMedCrossRefGoogle Scholar
  11. Stamler, et al. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–44.PubMedCrossRefGoogle Scholar
  12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:683–9.Google Scholar
  13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.Google Scholar

Copyright information

© Bohn Stafleu van Loghum, Houten 2008

Authors and Affiliations

  • L. Van Gaal
    • 1
  1. 1.Universitair Ziekenhuis AntwerpenEdegem

Personalised recommendations